Despite the impact from the novel coronavirus (Covid-19) lockdown measures, UOB KayHian is still bullish on Tianjin Zhong Xin Pharmaceutical Group Corp.

“We expect a strong rebound in 2H20 as China’s economy recovers and reopens,” UOBKH analysts Llelleythan Tan and John Cheong write in a note dated Aug 19.

According to UOBKH, Tianjin Zhong Xin’s 1H FY20 revenue and earnings were slightly below expectations, forming 44.5% and 46.1% of its full-year forecasts, respectively.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook